Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: CTS Clinical and Translational Science 15 (2022) 7, 1606-1612
- Event
-
Veröffentlichung
- (where)
-
Münster
- (who)
-
Universitäts- und Landesbibliothek Münster
- (when)
-
2023
- Creator
-
Trümpelmann, Susan
Schulte-Mecklenbeck, Andreas
Steinberg, Olga V.
Wirth, Timo
Fobker, Manfred
Lohmann, Lisa
Lünemann, Jan
Wiendl, Heinz
Gross, Catharina C.
Klotz, Luisa
- DOI
-
10.17879/39938516875
- URN
-
urn:nbn:de:hbz:6-89928468200
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:46 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Trümpelmann, Susan
- Schulte-Mecklenbeck, Andreas
- Steinberg, Olga V.
- Wirth, Timo
- Fobker, Manfred
- Lohmann, Lisa
- Lünemann, Jan
- Wiendl, Heinz
- Gross, Catharina C.
- Klotz, Luisa
- Universitäts- und Landesbibliothek Münster
Time of origin
- 2023
Other Objects (12)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions
Vaccination against SARS-CoV-2: a human enhancement story
XV. Humoral-Pathologie
Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response
Modifying adjuncts